Medicines & Healthcare products Regulatory Agency

MHRA

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms Heather House
UNIVERSITY OF OXFORD
CLINICAL TRIALS AND RESEARCH GOVERNANCE, JOINT RESEARCH OFFICE,
1ST FLOOR, BOUNDARY BROOK HOUSE, CHURCHILL DRIVE, HEADINGTON
OXFORD
OX3 7LQ
UNITED KINGDOM

25/03/2020

Dear Ms Heather House,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 21584/0423/001-0002
Eudract Number:	2020-001113-21
Product:	Lopinavir/ritonavir, Dexamethasone, Interferon beta-1a, Hydroxychloroquine
Protocol number:	NDPHRECOVERY
Substantial Amendment Code Number:	Code Number: SA1 Version: 1.0 Date: 2020/03/20

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 23/03/2020.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

Clinical Trials Unit
MHRA